Ankylosing Spondylitis

Upadacitinib significantly reduced signs and symptoms of both ankylosing spondylitis and nonradiographic axial spondyloarthritis, as well as improved physical function and disease activity, according to a pair of phase 3 studies from AbbVie.

Secukinumab improves non-radiographic axial spondyloarthritis signs and symptoms across patients grouped by C-reactive protein level, MRI score, HLA-B27 status and sex, according to data published in Arthritis Research & Therapy.

In contrast to some previous studies, an analysis of U.S. Army personnel found that the incidence of ankylosing spondylitis was similar between men and women, according to data published in Arthritis Care & Research.

Upadacitinib 15 mg demonstrates consistent, sustained efficacy in ankylosing spondylitis through year 1, according to data published in Arthritis & Rheumatology.

The FDA recently authorized sotrovimab to treat mild-to-moderate COVID-19 in individuals aged 12 years and older who are not hospitalized or require oxygen. The announcement was the top story in rheumatology last week.

Air pollution is a predictor of poor response to biological treatment in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, according to a poster session at the EULAR 2021 Congress.

Tofacitinib 2 mg twice daily demonstrated “significantly greater” efficacy than placebo in adults with ankylosing spondylitis, according to researchers writing in the Annals of the Rheumatic Diseases.

Women demonstrate higher axial spondyloarthritis disease burden, and more peripheral symptoms, than men, according to data published in The Journal of Clinical Rheumatology.

Maternal ankylosing spondylitis is associated with a 2.02-times higher likelihood of Kawasaki disease in the offspring, according to a research letter published in JAMA Network Open.

Researchers found significantly lower treatment rates for women with ankylosing spondyloarthritis in multiple studies analyzing clinical trials in axial spondylarthritis, resulting in poor outcomes and response to therapies once started.